OR WAIT null SECS
Cell Mogrify (Mogrify), has been granted funding by the UK’s innovation agency, Innovate UK, to accelerate regenerative cell therapies.
United Kingdom-based company, Cell Mogrify (Mogrify), has been granted £425,000 (approximately $555,000) in funding by the UK’s innovation agency, Innovate UK, to accelerate regenerative cell therapies.
In a March 18, 2019 press release, it was revealed that the funding will be used to support the application of Mogrify’s bioinformatics approach to transition three cell therapy products to preclinical stage. Presently, cells used in cell therapies are either extracted and sorted from a patient or donor; the cells that are derived using experimental protocols can take several years to develop. Through the use of its bioinformatics platform, Mogrify hopes to deliver an efficient, safe, and scalable source of cells, which can be used to develop personalized regenerative cell therapy products.
“We have already used our bioinformatic-approach to produce chondrocytes and microvascular endothelial cells by transdifferentiation and speed up the protocols for acquiring astrocytes, neurons, and chondrocytes from induced pluripotent stem cells,” explained Julian Gough, co-founder and CSO, Mogrify, in the press release. “We are already engaging with companies that would like us to support development of autologous and allogeneic T-cell therapies, and are confident that our technology has the potential to provide a platform technology on which any cell for cell therapy can be developed.”
“Mogrify’s mission is to place ourselves, and as a result the UK, at the forefront of the next generation of cell therapy companies. By embracing systematic data science approaches built on large-scale transcriptomic, cell regulatory network, and epigenetic data, we believe better cell therapies can be developed at a lower cost across all therapeutic areas,” added Darrin M. Disley, CEO, Mogrify. “The funding from Innovate UK will enable Mogrify to expand its portfolio of cell types and extend its reach into new therapeutics areas to address the global cell therapy opportunity, worth an estimated $30 billion USD.”